TCMDNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Tactile Systems Technology, Inc

Tactile Systems Technology is a U.S.-based medical technology company that develops and sells home-based devices for chronic disease management. Its core offerings address lymphedema, chronic venous insufficiency, and airway clearance therapy, with sales concentrated in the United States through a direct-to-patient and provider model.

Revenue330m USD
+12.5 %y/y
Operating profit (EBIT)29.3m USD
+32.0 %y/y
EBIT margin8.9%
+1.3 ppy/y
Net income19.1m USD
+12.5 %y/y
Free cash flow40.4m USD
+5.7 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-1000100200300400m USD2020: 187 m USD2020: EBIT -3.6 m USD20202021: 208 m USD2021: EBIT -1.8 m USD20212022: 247 m USD2022: EBIT -13 m USD20222023: 274 m USD2023: EBIT 18 m USD20232024: 293 m USD2024: EBIT 22 m USD20242025: 330 m USD2025: EBIT 29 m USD202533029
RevenueOperating profit (EBIT)

Business

Share of revenue
Lymphedema therapy systems78 %

Home-use pneumatic compression devices for lymphedema and related venous disease.

Airway clearance therapy22 %

Vest-based respiratory therapy devices used to help clear mucus in chronic lung conditions.

Products

Reported · share of revenue
84.5%15.5%FY2025100 %
  • Lymphedema Products84.5 %
  • Airway Clearance Products15.5 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

The company sells primarily to patients in the United States, with reimbursement and access shaped by physicians, payers, and durable medical equipment channels. Its products are used by people with chronic conditions such as lymphedema, chronic venous insufficiency, and respiratory disease, often after clinical referral and payer approval.

Lymphedema patients

Buy Flexitouch Plus, Entre Plus, and Nimbl systems for home treatment of swelling and related symptoms.

Chronic venous insufficiency patients

Use compression therapy devices to manage venous disease and related edema.

Respiratory patients

Buy AffloVest systems for airway clearance in chronic respiratory conditions.

Healthcare providers and payers

Influence product adoption through referrals, coverage decisions, and reimbursement pathways.

Strategy

The company’s strategy centers on expanding home-based treatment adoption for underserved chronic diseases through direct clinical and patient engagement. It emphasizes sales-force productivity, payer access, clinical evidence, and product expansion to strengthen its position in the U.S. home-therapy market.

Expand direct commercial reachShort term

A direct model helps the company control patient education, access, and conversion.

Strengthen reimbursement and payer accessShort term

Coverage criteria and billing privileges are central to device adoption and revenue realization.

Grow the product portfolioMedium term

New devices broaden the addressable market and reduce reliance on a single product line.

Geography

The business is concentrated in the United States, which is both its main sales market and operating base. The company also maintains trademark registrations in several non-U.S. markets, but the disclosed revenue base is overwhelmingly U.S.-centric.

Risks

The company depends heavily on Medicare coverage, payer criteria, and durable medical equipment accreditation, so reimbursement changes could materially affect demand and access. It also faces intense competition, technology change, and operational risks tied to direct sales, manufacturing, cybersecurity, and product performance.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Medicare coverage and reimbursement changes1Competitive pressure in pneumatic compression and airway clearance2Accreditation and licensing compliance3Cybersecurity and IT disruption4Product performance and recall risk5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Medicare coverage and reimbursement changesImpact: HighLikelihood: Medium

    A large share of patients rely on Medicare, so coverage criteria directly affect utilization and collections.

    Exposure: U.S. home-therapy revenue

  2. Competitive pressure in pneumatic compression and airway clearanceImpact: HighLikelihood: Medium

    Rivals with broader resources or distribution can pressure pricing, share, and customer acquisition.

    Exposure: Lymphedema and respiratory device markets

  3. Accreditation and licensing complianceImpact: HighLikelihood: Low

    The direct-to-patient model depends on maintaining DME certification and related approvals.

    Exposure: U.S. operating model

  4. Cybersecurity and IT disruptionImpact: MediumLikelihood: Medium

    Patient, billing, and operational systems are exposed to intrusion, outage, or data breach risk.

    Exposure: Commercial and reimbursement systems

  5. Product performance and recall riskImpact: MediumLikelihood: Medium

    Device defects can affect patient safety, trigger field actions, and damage reputation.

    Exposure: All device lines

Accounting

Judgemental items
Revenue recognition and collectability estimates

Device sales and rentals require judgment on expected payment and timing of recognition.

Impact: Can change reported revenue if payer or patient collections differ from estimates

Seasonality

Management discloses seasonal effects that can distort quarter-to-quarter comparisons.

Impact: Affects revenue and expense comparability across periods

Contingent consideration / earn-out fair value

The AffloVest earn-out was remeasured to fair value until the earn-out period ended.

Impact: Can create non-cash gains or losses in the income statement

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Tactile Systems Technology, Inc (TCMD) Revenue, Earnings & Financials 2025 – Clarifo